Treat Biliary Cancer!
Time of Update: 2022-05-01
ZW25 for injection as a single agent for the treatment of HER2-positive locally advanced unresectable or metastatic biliary tract cancer (BTC) that has failed previous systemic chemotherapy .
VESPER study: dd-MVAC neoadjuvant chemotherapy significantly improves 3-year PFS in non-metastatic muscle-invasive bladder cancer
Time of Update: 2022-04-29
The results showed that HR of the treatment groups differed significantly by chemotherapy regimen, suggesting that adjuvant chemotherapy and NAC should not be used in combination (Table 2) .
Darotamide combined with ADT improves survival in patients with hormone-sensitive metastatic prostate cancer
Time of Update: 2022-04-28
ADT Intensification in Hormone-Sensitive Metastatic Prostate Cancer: A Review of Evolving Treatment Options by Robert Dreicer, MD, MS , MACP, FASCO Addition of dalotamide to androgen deprivation therapy combined with docetaxel improves survival .
[Nature Sub-Journal] Identify ways to limit the growth of metastatic cancer!
Time of Update: 2022-04-27
This study deciphers the role of cancer stem cell (CSCs)-regulated phenotypic plasticity in metastatic colonization and provides a therapeutic approach to limit metastatic growth .
Metastatic prostate cancer on the rise as cancer screenings decline
Time of Update: 2022-04-26
A new study from Keck Medicine at USC has found a significant increase in the incidence of metastatic prostate cancer in men 45 and older, in line with recommendations against routine prostate cancer screening .
-line or above in the treatment of patients with refractory metastatic colorectal cancer (mCRC)
Time of Update: 2022-04-24
, respectively . The most common starting dose of regorafenib was 80 mg (94 [53. 1%]) . >The median
Assessing the invasive and metastatic potential of cancer cells from tissue sections
Time of Update: 2022-04-24
Using this approach, the team found that by agitating a solution containing molecular probes that bind to Rac/Cdc42 activated on cancer tissue sections, they were able to rapidly and definitively assess colon cancer cell motility and invasive capacity .
Clin Cancer Res: Combination of cetuximab and nivolumab in the treatment of recurrent/metastatic head and neck squamous cell carcinoma
Time of Update: 2022-04-24
InfectThis is a multi-institutional phase 2 clinical trial to determine the overall efficacy of cetuximab plus nivolumab in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) Survival rate (OS) .
in advanced or metastatic non-small cell lung cancer (NSCLC): KCSG LU20-11
Time of Update: 2022-04-24
To assess long-term survival outcomes in patients with advanced or metastatic non-small cell lung cancer (NSCLC) who have completed 2 years of immunotherapy (ICI) or been discontinued after 6 months of immunotherapy without progression .
with Opdivo(R) in Patients with Locally Advanced or Metastatic Gastric Cancer/Gastroesophageal Junction Cancer
Time of Update: 2022-04-23
To evaluate the safety, tolerability and anti-tumor efficacy of TST001 combined with Opdivo® in patients with unresectable locally advanced or metastatic gastric cancer and gastroesophageal junction cancer expressing Claudin18.
NEJM: Effect of dalolutamide on survival in metastatic hormone-sensitive prostate cancer
Time of Update: 2022-04-23
>. >>In this international phase 3 trial, researchers randomly assigned patients with metastatic hormone-sensitive prostate cancer in a 1:1 ratio to receive dalolutamide (at a dose of 600 mg). [two 300
NEJM: Trastuzumab deruxtecan vs Trastuzumab emtansine in HER2-positive metastatic breast cancer
Time of Update: 2022-04-23
The researchers reported the efficacy of trastuzumab deruxtecan in the treatment of breast cancer patients with disease progression after trastuzumab plus paclitaxel .
Clin Oncol: Efficacy of FOLFIRI combined with bevacizumab versus FOLFIRI combined with aflibercept in the second-line treatment of metastatic colorectal cancer
Time of Update: 2022-04-23
>>Original source:Jo H, Lee MS, Lee YP, Kim H, Hong JY, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim ST. A Comparison of Folinic Acid, Fluorouracil and Irinotecan
but improves OS in patients with irinotecan-refractory metastatic colorectal cancer (mCRC)
Time of Update: 2022-04-23
Recently, a related study was published in the journal Oncologist, in patients with irinotecan-refractory metastatic colorectal cancer (mCRC) who had not previously received anti-EGFR therapy, the addition of cetuximab + irinotecan.
Clin Cancer Res: Efficacy and safety of ramucirumab in the treatment of advanced biliary tract cancer
Time of Update: 2022-04-23
Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated by Gemcitabine-based Chemotherapy.
intraperitoneal chemotherapy (HIPEC) in patients with metastatic colorectal cancer (mCRC) with peritoneal metastasis (PM)
Time of Update: 2022-04-23
/>3%) had MSI . Among mutBRAF tumors, MSI was more common in cases with both PM-CRC (50% vs 17. 9%, P=0. 047) and poorly differentiated tumors (83. 8% vs 15. 4%, P<
J Clin Oncol: Efficacy of temozolomide in combination with low-dose ipilimumab and nivolumab in MSS and MGMT-deficient metastatic colorectal cancer (mCRC)
Time of Update: 2022-04-22
The primary endpoint was the 8-month progression-free survival (PFS) rate (calculated from the second part of treatment) .
